Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-β activation in the kidneys of rats used as a model of diabetes
Diabetologia, Volume 51, No. 9, Year 2008
Notification
URL copied to clipboard!
Description
Aims/hypothesis: The selective CuII chelator triethylenetetramine (TETA) extracts systemic CuII into the urine of diabetic humans and rats as a model of diabetes, and in the process also normalises hallmarks of diabetic heart disease. However, the role of Cu and its response to TETA in animals with diabetic nephropathy were previously unknown. Here, we report the effects of TETA treatment on Cu and other essential elements, as well as on indices of renal injury and known pathogenic molecular processes, in kidneys from a rat model of diabetes. Methods: Rats at 8 weeks after streptozotocin-induction of diabetes were treated with oral TETA (34 mg/day in drinking water) for a further 8 weeks and then compared with untreated diabetic control animals. Results: Renal tissue Cu was substantively elevated by diabetes and normalised by TETA, which also suppressed whole-kidney and glomerular hypertrophy without lowering blood glucose. The urinary albumin: creatinine ratio was significantly elevated in the rat model of diabetes but lowered by TETA. Total collagen was also elevated in diabetic kidneys and significantly improved by TETA. Furthermore, renal cortex levels of TGF-β1, MAD homologue (SMAD) 4, phosphorylated SMAD2, fibronectin-1, collagen-III, collagen-IV, plasminogen activator inhibitor-1 and semicarbazide-sensitive amine oxidase all tended to be elevated in diabetes and normalised by TETA. Conclusions/interpretation: Dysregulation of renal Cu homeostasis may be a key event eliciting development of diabetic nephropathy. Selective CuII chelation can protect against pathogenic mechanisms that lead to or cause diabetic nephropathy and might be clinically useful in the treatment of early-stage diabetic kidney disease. © 2008 Springer-Verlag.
Authors & Co-Authors
Gong, Deming
New Zealand, Auckland
The University of Auckland
Lu, Jun
New Zealand, Auckland
The University of Auckland
Kennedy, John Vedamuthu
New Zealand, Lower Hutt
Gns Science
Barry, Bernard J.
New Zealand, Lower Hutt
Gns Science
Chan, Yih Kai
New Zealand, Auckland
The University of Auckland
Phillips, Anthony RJ J.
New Zealand, Auckland
The University of Auckland
New Zealand, Auckland
Maurice Wilkins Centre for Molecular Biodiscovery
Cooper, Garth J.S.
New Zealand, Auckland
The University of Auckland
New Zealand, Auckland
Maurice Wilkins Centre for Molecular Biodiscovery
United Kingdom, Oxford
Mrc Immunochemistry Unit
Statistics
Citations: 73
Authors: 7
Affiliations: 4
Identifiers
Doi:
10.1007/s00125-008-1088-7
ISSN:
0012186X
Research Areas
Environmental
Health System And Policy
Noncommunicable Diseases
Violence And Injury